- Technology/Device
- Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
-
Wenqi Fan, Chao Deng, Ruoyao Xu, Zhenqi Liu, Richard David Leslie, Zhiguang Zhou, Xia Li
-
Diabetes Metab J. 2025;49(2):235-251. Published online November 13, 2024
-
DOI: https://doi.org/10.4093/dmj.2024.0130
-
-
3,577
View
-
266
Download
-
1
Web of Science
-
4
Crossref
-
 Abstract
 PDF Supplementary Material PubReader  ePub
- Background
Automated insulin delivery (AID) systems studies are upsurging, half of which were published in the last 5 years. We aimed to evaluate the efficacy and safety of AID systems in patients with type 1 diabetes mellitus (T1DM).
Methods
We searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov until August 31, 2023. Randomized clinical trials that compared AID systems with other insulin-based treatments in patients with T1DM were considered eligible. Studies characteristics and glycemic metrics was extracted by three researchers independently.
Results
Sixty-five trials (3,623 patients) were included. The percentage of time in range (TIR) was 11.74% (95% confidence interval [CI], 9.37 to 14.12; P<0.001) higher with AID systems compared with control treatments. Patients on AID systems had more pronounced improvement of time below range when diabetes duration was more than 20 years (–1.80% vs. –0.86%, P=0.031) and baseline glycosylated hemoglobin lower than 7.5% (–1.93% vs. –0.87%, P=0.033). Dual-hormone full closed-loop systems revealed a greater improvement in TIR compared with hybrid closed-loop systems (–19.64% vs. –10.87%). Notably, glycemia risk index (GRI) (–3.74; 95% CI, –6.34 to –1.14; P<0.01) was also improved with AID therapy.
Conclusion
AID systems showed significant advantages compared to other insulin-based treatments in improving glucose control represented by TIR and GRI in patients with T1DM, with more favorable effect in euglycemia by dual-hormone full closedloop systems as well as less hypoglycemia for patients who are within target for glycemic control and have longer diabetes duration.
-
Citations
Citations to this article as recorded by  - Transitioning between automated insulin delivery systems: A focus on personalisation
Pilar Isabel Beato-Víbora, Ana Chico, Jesus Moreno-Fernandez, Sharona Azriel-Mira, Lia Nattero-Chávez, Rosario Vallejo Mora, Núria Alonso-Carril, Olga Simó-Servat, Eva Aguilera-Hurtado, Luz María Reyes Céspedes, Marisol Ruiz de Adana, Marta Domínguez, Ros
Diabetes Research and Clinical Practice.2025; 222: 112070. CrossRef - Advances in Continuous Glucose Monitoring: Clinical Applications
So Yoon Kwon, Jun Sung Moon
Endocrinology and Metabolism.2025; 40(2): 161. CrossRef - Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis (Diabetes Metab J 2025;49:235-51)
Wenqi Fan, Chao Deng, Zhiguang Zhou, Xia Li
Diabetes & Metabolism Journal.2025; 49(3): 520. CrossRef - Critical Insights into the Efficacy and Safety of Automated Insulin Delivery Systems in Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2025;49:235-51)
Sami Ullah, Ayesha Ahmad, Kamil Ahmad Kamil, Minahil Laraib Asif, Abdullah Jan
Diabetes & Metabolism Journal.2025; 49(3): 516. CrossRef
- Technology/Device
- Glutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function
-
Yuxiao Zhu, Li Qian, Qing Liu, Jing Zou, Ying Zhou, Tao Yang, Gan Huang, Zhiguang Zhou, Yu Liu
-
Diabetes Metab J. 2020;44(2):260-266. Published online November 12, 2019
-
DOI: https://doi.org/10.4093/dmj.2019.0007
-
-
7,772
View
-
143
Download
-
15
Web of Science
-
17
Crossref
-
Abstract
PDFPubReader
- Background
The detection of glutamic acid decarboxylase 65 (GAD65) autoantibodies is essential for the prediction and diagnosis of latent autoimmune diabetes in adults (LADA). The aim of the current study was to compare a newly developed electrochemiluminescence (ECL)-GAD65 antibody assay with the established radiobinding assay, and to explore whether the new assay could be used to define LADA more precisely. MethodsSerum samples were harvested from 141 patients with LADA, 95 with type 1 diabetes mellitus, and 99 with type 2 diabetes mellitus, and tested for GAD65 autoantibodies using both the radiobinding assay and ECL assay. A glutamic acid decarboxylase antibodies (GADA) competition assay was also performed to assess antibody affinity. Furthermore, the clinical features of these patients were compared. ResultsEighty-eight out of 141 serum samples (62.4%) from LADA patients were GAD65 antibody-positive by ECL assay. Compared with ECL-GAD65 antibody-negative patients, ECL-GAD65 antibody-positive patients were leaner (P<0.0001), had poorer β-cell function (P<0.05), and were more likely to have other diabetes-associated autoantibodies. The β-cell function of ECL-GAD65 antibody-positive patients was similar to that of type 1 diabetes mellitus patients, whereas ECL-GAD65 antibody-negative patients were more similar to type 2 diabetes mellitus patients. ConclusionPatients with ECL-GAD65 antibody-negative share a similar phenotype with type 2 diabetes mellitus patients, whereas patients with ECL-GAD65 antibody-positive resemble those with type 1 diabetes mellitus. Thus, the detection of GADA using ECL may help to identify the subtype of LADA.
-
Citations
Citations to this article as recorded by - 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo, Kirthikaa Balapattabi, Elizabeth A. Beverly, Kathaleen Briggs Early, Dennis Bruemmer, Osagie Ebekozien, Justin B. Echouffo-Tcheugui, Laya Ekhlaspour, Jason L. Gaglia, Rajesh Garg, Kamlesh Khunti, Rayhan L
Diabetes Care.2025; 48(Supplement): S27. CrossRef - Enhanced Electrochemiluminescence from Ruthenium-Tagged Immune Complex at Flexible Chains for Sensitive Analysis of Glutamate Decarboxylase Antibody
Yuyao Zhang, Li Qian, Qian Zhang, Yu Li, Yu Liu, Dechen Jiang
Biosensors.2025; 15(1): 47. CrossRef - Early prediction of diabetics using three-layer classifier model and improved dimensionality reduction
Keerthana G, Mohanasundaram R
Multimedia Tools and Applications.2025;[Epub] CrossRef - 2. Diagnosis and Classification of Diabetes:Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pil
Diabetes Care.2024; 47(Supplement): S20. CrossRef - Vitamin D Supplementation as a Therapeutic Strategy in Autoimmune Diabetes: Insights and Implications for LADA Management
Niki G. Mourelatou, Dimitris Kounatidis, Edward B. Jude, Eleni Rebelos
Nutrients.2024; 16(23): 4072. CrossRef - 2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Jason L. Gaglia, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Jose Leon, Sarah K. Lyons, Mary
Diabetes Care.2023; 46(Supplement): S19. CrossRef - Determination of autoantibodies in type 2 diabetes: one simple way to improve classification
Johnny Ludvigsson
Diabetologia.2023; 66(5): 955. CrossRef - 2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2022
Diabetes Care.2022; 45(Supplement): S17. CrossRef - Screening Strategy for Islet Autoantibodies in Diabetes Patients of Different Ages
Xixi Nan, Xia Li, Yufei Xiang, Xiang Yan, Houde Zhou, Xiaohan Tang, Jin Cheng, Xiaohong Niu, Jing Liu, Qiuhe Ji, Linong Ji, Gan Huang, Zhiguang Zhou
Diabetes Technology & Therapeutics.2022; 24(3): 212. CrossRef - Atypical Diabetes and Management Considerations
Shivajirao Prakash Patil
Primary Care: Clinics in Office Practice.2022; 49(2): 225. CrossRef - Latent autoimmune diabetes in adults: a focus on β-cell protection and therapy
Wenfeng Yin, Shuoming Luo, Zilin Xiao, Ziwei Zhang, Bingwen Liu, Zhiguang Zhou
Frontiers in Endocrinology.2022;[Epub] CrossRef - Analysis of detrended fluctuation function derived from continuous glucose monitoring may assist in distinguishing latent autoimmune diabetes in adults from T2DM
Liyin Zhang, Qi Tian, Keyu Guo, Jieru Wu, Jianan Ye, Zhiyi Ding, Qin Zhou, Gan Huang, Xia Li, Zhiguang Zhou, Lin Yang
Frontiers in Endocrinology.2022;[Epub] CrossRef - Prevalence of antibodies targeting ubiquitin-conjugating enzyme 2L3 and eukaryote translation elongation factor 1 α1 in Chinese Han and American Caucasian populations with type 1 diabetes
Li Qian, Yuxiao Zhu, Yan Luo, Mu Zhang, Liping Yu, Yu Liu, Tao Yang
Endocrine Connections.2022;[Epub] CrossRef - 2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2021
Diabetes Care.2021; 44(Supplement): S15. CrossRef - High-Affinity ZnT8 Autoantibodies by Electrochemiluminescence Assay Improve Risk Prediction for Type 1 Diabetes
Xiaofan Jia, Ling He, Dongmei Miao, Kathleen Waugh, Cristy Geno Rasmussen, Fran Dong, Andrea K Steck, Marian Rewers, Liping Yu
The Journal of Clinical Endocrinology & Metabolism.2021;[Epub] CrossRef - Lada or Type 2 Diabetes Mellitus - A Challenging Diagnosis in Clinical Approach
Lucia Mihaela Custură, Oana Deteşan, Raluca Maria Tilinca, Reka Annamaria Schmiedt, Brigitta Irén Bacso, Mariana Cornelia Tilinca
Acta Medica Transilvanica.2021; 26(3): 55. CrossRef - A fluorescence enhancement assay for measurement of glutamate decarboxylase activity
Messripour Manoochehr, Mesripour Azadeh
Open Journal of Analytical and Bioanalytical Chemistry.2020; : 007. CrossRef
|
KDA
